Use of interleukin-19 to treat cervical cancer

Abstract

The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of cervical cancer cells, treating cervical cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.

1 . A method of reducing proliferation of cervical cancer cells comprising administering to a mammal with a cervical neoplasm an amount of a composition of IL-19 polypeptide sufficient to reduce proliferation of the neoplastic cervical cells.  
     
     
         2 . The method of  claim 1 , wherein the IL-19 polypeptide is administered in conjunction with radiation.  
     
     
         3 . The method of  claim 1 , wherein the IL-19 polypeptide is administered in conjunction with a chemotherapeutic agent.  
     
     
         4 . The method of  claim 2 , wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.  
     
     
         5 . The method of  claim 1 , wherein the IL-19 polypeptide is fused with a cytotoxic moiety.  
     
     
         6 . The method of  claim 5 , wherein the cytotoxic moiety is a bacterial or plant toxin, cytotoxic radionuclide or cytotoxic drug.  
     
     
         7 . A method of reducing proliferation of cervical cells comprising administering to a mammal with a human papillomavirus infection, cervical dysplasia, cervical intraepithelial neoplasia, or carcinoma of the cervix, an amount of a composition of IL-19 polypeptide sufficient to reduce proliferation of the cervical cells, wherein the IL-19 polypeptide is fused with a cytotoxic moiety.  
     
     
         8 . The method of  claim 7 , wherein the IL-19 polypeptide is administered in conjunction with radiation  
     
     
         9 . The method of  claim 8 , wherein the IL-19 polypeptide is administered in conjunction with a chemotherapeutic agent.  
     
     
         10 . The method of  claim 9 , wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.  
     
     
         11 . The method of  claim 8 , wherein the cytotoxic moiety is a bacterial or plant toxin, cytotoxic radionuclide or cytotoxic drug.